Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.

The American journal of gastroenterology·2018

Same author

Individualized lung recruitment maneuver guided by pulse-oximetry in anesthetized patients undergoing laparoscopy: a feasibility study.

Acta anaesthesiologica Scandinavica·2018

Same author

Erratum: Observation of the hyperfine spectrum of antihydrogen.

Nature·2017

Same author

Correlates of ideal cardiovascular health in European adolescents: The HELENA study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017

Same author

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Antihydrogen accumulation for fundamental symmetry tests.

Nature communications·2017

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Hematopoietic SCT for peripheral T-cell lymphoma.

A Gutiérrez¹, M D Caballero, G Pérez-Manga

¹Department of Haematology, University Hospital Son Dureta, Palma de Mallorca, Spain.

Bone Marrow Transplantation

|October 22, 2008

Summary

Hematopoietic stem cell transplant (HSCT) offers improved outcomes for high-risk peripheral T-cell lymphoma (PTCL) patients. Both autologous and allogeneic HSCT show promise, with ongoing trials exploring optimal strategies.

More Related Videos

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Isolation of CD4⁺ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Isolation of CD4⁺ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

Area of Science:

Hematology
Oncology
Transplant Immunology

Background:

High-risk peripheral T-cell lymphoma (PTCL) shows poor outcomes with conventional chemotherapy.
Aggressive B-cell lymphomas have better responses to current treatments than PTCL.
Hematopoietic stem cell transplantation (HSCT) is being investigated for PTCL management.

Purpose of the Study:

To review current data on HSCT for high-risk PTCL in frontline and salvage settings.
To evaluate the efficacy and safety of autologous (ASCT) and allogeneic (Allo-SCT) stem cell transplantation in PTCL.
To identify areas for improvement in HSCT strategies for PTCL.

Main Methods:

Review of retrospective studies and prospective clinical trials on HSCT in PTCL.
Analysis of outcomes including progression-free survival (PFS) and treatment-related mortality (TRM).
Evaluation of graft-versus-PTCL effects in allogeneic HSCT.

Main Results:

ASCT in the salvage setting shows efficacy comparable to aggressive B-cell lymphomas.
Frontline ASCT consolidation in complete responders yields good results (long-term PFS >50%) with low TRM (<5%).
Approximately 25% of patients do not receive ASCT due to disease progression; 25-30% relapse post-ASCT.
Preliminary evidence suggests Allo-SCT may induce a survival plateau (long-term PFS ~50%) due to graft-versus-PTCL effect.

Conclusions:

ASCT is a viable option for high-risk PTCL, particularly in the frontline consolidation setting for complete responders.
Strategies to enhance chemosensitivity and reduce post-transplant relapse are needed.
Allo-SCT warrants further investigation in ongoing clinical trials for chemoresistant PTCL.